Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P63096

UPID:
GNAI1_HUMAN

ALTERNATIVE NAMES:
Adenylate cyclase-inhibiting G alpha protein

ALTERNATIVE UPACC:
P63096; A8KA88; B4E2V1; C9J3A4; P04898; P11015; P31871; Q5U074; Q8TAN5; Q9UGA4

BACKGROUND:
Guanine nucleotide-binding protein G(i) subunit alpha-1, alternatively named Adenylate cyclase-inhibiting G alpha protein, is crucial for GPCR-mediated signal transduction. It regulates the conversion of GTP to GDP, thereby controlling signaling duration. Its activity affects adenylate cyclase, leading to changes in cAMP levels, and plays a role in cell division and membrane organization.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in a neurodevelopmental disorder characterized by developmental delays, epilepsy, and behavioral issues, targeting Guanine nucleotide-binding protein G(i) subunit alpha-1 presents a promising avenue for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.